These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9250239)

  • 21. Three-year results of the Finnish prostate cancer screening trial.
    Määttänen L; Auvinen A; Stenman UH; Tammela T; Rannikko S; Aro J; Juusela H; Hakama M
    J Natl Cancer Inst; 2001 Apr; 93(7):552-3. PubMed ID: 11287450
    [No Abstract]   [Full Text] [Related]  

  • 22. Prostate-specific antigen and prostate cancer prognosis.
    Church TR
    J Natl Cancer Inst; 2006 Nov; 98(21):1509-10. PubMed ID: 17077347
    [No Abstract]   [Full Text] [Related]  

  • 23. Screening for prostate cancer in the UK. Seems to be creeping in by the back door.
    Donovan JL; Frankel SJ; Neal DE; Hamdy FC
    BMJ; 2001 Oct; 323(7316):763-4. PubMed ID: 11588064
    [No Abstract]   [Full Text] [Related]  

  • 24. The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population-based prostate cancer screening trial.
    Carlsson S; Aus G; Bergdahl S; Khatami A; Lodding P; Stranne J; Hugosson J
    Eur J Cancer; 2011 Mar; 47(4):545-53. PubMed ID: 21087857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ethics of a prostate cancer screening trial.
    Adami HO; Baron JA; Rothman KJ
    Lancet; 1994 Apr; 343(8903):958-60. PubMed ID: 7512680
    [No Abstract]   [Full Text] [Related]  

  • 26. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.
    Chou R; Croswell JM; Dana T; Bougatsos C; Blazina I; Fu R; Gleitsmann K; Koenig HC; Lam C; Maltz A; Rugge JB; Lin K
    Ann Intern Med; 2011 Dec; 155(11):762-71. PubMed ID: 21984740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Hamilton RJ; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
    [No Abstract]   [Full Text] [Related]  

  • 28. [Prostate cancer and care. When male intimacy is put to the test...].
    Héron M
    Soins; 2007 Mar; (713):31. PubMed ID: 17419565
    [No Abstract]   [Full Text] [Related]  

  • 29. The benefits of, controversies surrounding, and professional recommendations for routine PSA testing: what do men believe?
    Zemencuk JK; Hayward RA; Katz SJ
    Am J Med; 2001 Mar; 110(4):309-13. PubMed ID: 11239850
    [No Abstract]   [Full Text] [Related]  

  • 30. Prostate-specific antigen dynamics and prostate cancer diagnosis.
    Bartoletti R
    Eur Urol; 2009 Nov; 56(5):761-2; discussion 763. PubMed ID: 19665286
    [No Abstract]   [Full Text] [Related]  

  • 31. Part 2: Patient information, informed decision-making and the psycho-social impact of prostate-specific antigen testing.
    Hewitson P; Austoker J
    BJU Int; 2005 Apr; 95 Suppl 3():16-32. PubMed ID: 15844284
    [No Abstract]   [Full Text] [Related]  

  • 32. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
    Carroll PR; Whitson JM; Cooperberg MR
    J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
    [No Abstract]   [Full Text] [Related]  

  • 33. The cautionary tale of PSA testing.
    Hoffman RM; Zeliadt SB
    Arch Intern Med; 2010 Jul; 170(14):1262-3. PubMed ID: 20660847
    [No Abstract]   [Full Text] [Related]  

  • 34. New trial data do not end the PSA screening debate.
    Vastag B
    J Natl Cancer Inst; 2009 Jun; 101(12):844-5. PubMed ID: 19509364
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy vs effectiveness in prostate-specific antigen screening.
    Albertsen PC
    J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of prostate-specific antigen screening on the natural history of prostate cancer.
    Rosen MA
    Urology; 1995 Dec; 46(6):757-68. PubMed ID: 7502411
    [No Abstract]   [Full Text] [Related]  

  • 37. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.
    Crouzet S; Chapelon JY; Rouvière O; Mege-Lechevallier F; Colombel M; Tonoli-Catez H; Martin X; Gelet A
    Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How valuable is prostate-specific antigen screening?
    Handler S
    Minn Med; 1996 Jun; 79(6):2. PubMed ID: 8692130
    [No Abstract]   [Full Text] [Related]  

  • 39. Kiwi conundrum: Screening for prostate cancer.
    Kuska B
    J Natl Cancer Inst; 1997 Jul; 89(14):1000. PubMed ID: 9244811
    [No Abstract]   [Full Text] [Related]  

  • 40. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
    Roobol MJ; Schröder FH; van Leenders GL; Hessels D; van den Bergh RC; Wolters T; van Leeuwen PJ
    Eur Urol; 2010 Dec; 58(6):893-9. PubMed ID: 20933321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.